KASL clinical practice guidelines for management of chronic hepatitis B

Korean Association for the Study of the Liver (KASL)

논문KCI 등재

KASL clinical practice guidelines for management of chronic hepatitis B

Korean Association for the Study of the Liver (KASL)

대한간학회 (The korean Association for the Study of the Liver)|2019.06|Clinical and Molecular Hepatology|제25권 제2호|pp. 93-159

1

조회

0

다운로드

43

인용

0

참고문헌

키워드

Treatment Chronic hepatitis B KASL guidelines

참고문헌 (587)

Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)
Chae HB, "Current status of liver diseases in Korea: hepatitis B", The Korean Journal of Hepatology, 15(Suppl 6), pp.S13~S24 (2009)
김보현, "Epidemiology of liver cancer in South Korea", Clinical and Molecular Hepatology, 24(1), pp.1~9 (2018), 대한간학회
Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
Hui CK, "Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase", Hepatology, 46, pp.395~401 (2007)
Tran TT, "Immune tolerant hepatitis B: a clinical dilemma", Gastroenterol Hepatol(NY), 7, pp.511~516 (2011)
Chu CM, "Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels", Am J Med, 116, pp.829~834 (2004)
Mason WS, "HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant", Gastroenterology, 151, pp.986~998 (2016)[DOI]
Livingston SE, "Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F", Gastroenterology, 133, pp.1452~1457 (2007)
Tsai SL, "Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion", J Clin Invest, 89, pp.87~96 (1992)
Lee PI, "Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children", Hepatology, 12(4), pp.657~660 (1990)
Lok AS, "Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology", J Hepatol, 10, pp.29~34 (1990)
McMahon BJ, "The natural history of chronic hepatitis B virus infection", Hepatology, 49(5 Suppl), pp.S45~S55 (2009)
Bortolotti F, "Chronic hepatitis B in children after e antigen seroclearance : final report of a 29-year longitudinal study", Hepatology, 43, pp.556~562 (2006)
Hsu YS, "Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B", Hepatology, 35, pp.1522~1527 (2002)
Lok AS, "Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection", Gastroenterology, 92, pp.1839~1843 (1987)
Yim HJ, "Natural history of chronic hepatitis B virus infection:what we knew in 1981 and what we know in 2005", Hepatology, 43(2), pp.S173~S181 (2005)
Sheen IS, "Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis", Gastroenterology, 89, pp.732~735 (1985)
Martinot-Peignoux M, "Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers", J Hepatol, 36, pp.543~546 (2002)
Zacharakis GH, "Natural history of chronic HBV infection : a cohort study with up to 12 years follow-up in North Greece(part of the Interreg I-II", EC-project), 2005, pp.77, 173~179
de Franchis R, "The natural history of asymptomatic hepatitis B surface antigen carriers", Ann Intern Med, 118, pp.191~194 (1993)
Fattovich G, "Natural history and prognosis of hepatitis B", Semin Liver Dis, 23, pp.47~58 (2003)
Chen YC, "Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection", Gastroenterology, 123, pp.1084~1089 (2002)
Lok AS, "Chronic hepatitis B : update 2009", Hepatology, 50, pp.661~662 (2009)
Funk ML, "World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants", J Viral Hepat, 9, pp.52~61 (2002)
Lok AS, "Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal", Proc Natl Acad Sci U S A, 91, pp.4077~4081 (1994)
Okamoto H, "Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen", J Virol, 68, pp.8102~8110 (1994)
Croagh CM, "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B", Liver Int, 30, pp.1115~1122 (2010)
Yoo BC, "Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea", J Hepatol, 38, pp.98~103 (2003)
Raimondo G, "Statements from the Taormina expert meeting on occult hepatitis B virus infection", J Hepatol, 49, pp.652~657 (2008)
Chu CM, "HBsAg seroclearance in asymptomatic carriers of high endemic areas : appreciably high rates during a long-term follow-up", Hepatology, 45, pp.1187~1192 (2007)
Liu J, "Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance : a community-based follow-up study", Gastroenterology, 139, pp.474~482 (2010)
Liaw YF, "Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection : a prospective study", Hepatology, 13, pp.627~631 (1991)
남순우, "Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection", The Korean Journal of Internal Medicine, 22(2), pp.73~76 (2007), 대한내과학회
Kuang XJ, "Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance", J Viral Hepat, 25, pp.1026~1037 (2018)
Yip TC, "Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance", J Hepatol, 67, pp.902~908 (2017)
Lee KJ, "Natural history of chronic hepatitis type B throughout long-term follow-up", Korean J Gastroenterol, 29, pp.343~351 (1997)
Liu S, "Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma : a meta-analysis", J Natl Cancer Inst, 101, pp.1066~1082 (2009)
Yang HI, "Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.1134~1143 (2008)
Tseng TC, "Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers", Gut, 64, pp.292~302 (2015)
Jang JW, "Mutational complex genotype of the hepatitis B virus X", precore regions as a novel predictive marker for hepatocellular carcinoma, 2012, pp.103, 296~304
Kim JK, "Specific mutations in the enhancer II", core promoter, J Med Virol, pp.2009, 81[DOI]
Kao JH, "Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers", Gastroenterology, 124, pp.327~334 (2003)
Wei F, "The association between hepatitis B mutants and hepatocellular carcinoma: a meta-analysis", Medicine (Baltimore), 96, pp.e6835~ (2017)
Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
Fattovich G, "Hepatocellular carcinoma in cirrhosis: incidence and risk factors", Gastroenterology, 127(5), pp.S35~S50 (2004)
Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
Bravi F, "Coffee and the risk of hepatocellular carcinoma and chronic liver disease : a systematic review and meta-analysis of prospective studies", Eur J Cancer Prev, 26, pp.368~377 (2017)
Kennedy OJ, "Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma : a systematic review and dose-response meta-analysis", BMJ Open, 7, pp.e013739~ (2017)
Petrick JL, "Coffee consumption and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by sex : the liver cancer pooling project", Cancer Epidemiol Biomarkers Prev, 24, pp.1398~1406 (2015)
Zhou YY, "Systematic review with network meta-analysis : antidiabetic medication and risk of hepatocellular carcinoma", Sci Rep, 6, pp.33743~ (2016)
Hwang IC, "Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults", Sci Rep, 8, pp.4968~ (2018)
Lee M, "Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment", Hepatology, 66, pp.1556~1569 (2017)
Chen CI, "Cancer risk in HBV patients with statin and metformin use: a population-based cohort study", Medicine(Baltimore), 94, pp.e462~ (2015)
Hsiang JC, "Statin and the risk of hepatocellular carcinoma and death in a hospitalbased hepatitis B-infected population : a propensity score landmark analysis", J Hepatol, 63, pp.1190~1197 (2015)
Kim G, "Statin use and the risk of hepatocellular carcinoma in patients at high risk : a nationwide nested case-control study", J Hepatol, 68, pp.476~484 (2018)
Pradelli D, "Statins and primary liver cancer : a meta-analysis of observational studies", Eur J Cancer Prev, 22, pp.229~234 (2013)
Singh S, "Statins are associated with a reduced risk of hepatocellular cancer : a systematic review and meta-analysis", Gastroenterology, 144, pp.323~332 (2013)
Zhou YY, "Systematic review with network meta-analysis : statins and risk of hepatocellular carcinoma", Oncotarget, 7, pp.21753~21762 (2016)
Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACH-B) : development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
Lee HW, "Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy", Am J Gastroenterol, 109, pp.1241~1249 (2014)
Jung KS, "Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy", Hepatology, 62, pp.1757~1766 (2015)
Papatheodoridis G, "PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy", J Hepatol, 64, pp.800~806 (2016)
Kim MN, "Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir", Liver Int, 37, pp.1788~1795 (2017)
Kim JH, "Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy", J Hepatol, 69, pp.1066~1073 (2018)
Cho EJ, "Current status and strategies for hepatitis B control in Korea", Clin Mol Hepatol, 23, pp.205~211 (2017)
Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
Kim DK, "Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older-United States, 2017", MMWR Morb Mortal Wkly Rep, 66, pp.136~138 (2017)
Mast EE, "A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents", MMWR Recomm Rep, 54(RR-16), pp.1~31 (2005)
Mast EE, "A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults", MMWR Recomm Rep, 55(RR-16), pp.1~33 (2006)
U.S. Public Health Service, "Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis", MMWR Recomm Rep, 50(RR-11), pp.1~52 (2001)
Lok AS, "Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection : implications in hepatitis B vaccination programs", Hepatology, 8, pp.766~770 (1988)
McMahon BJ, "Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen", Gastroenterology, 103, pp.590~594 (1992)
Keeffe EB, "Hepatitis A and B superimposed on chronic liver disease : vaccine-preventable diseases", Trans Am Clin Climatol Assoc, 117, pp.227~237 (2006)
Craig AS, "Prevention of hepatitis A with the hepatitis A vaccine", N Engl J Med, 350, pp.476~481 (2004)
Beasley RP, "Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine", Lancet, 2, pp.1099~1102 (1983)
Eke AC, "Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus", Cochrane Database Syst Rev, 2, pp.CD008545~ (2017)
Chen X, "Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus", PLoS One, 8, pp.e55303~ (2013)
Beasley RP, "Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B", Lancet, 2, pp.740~741 (1975)
Chevillotte G, "Interaction between hepatitis b virus and alcohol consumption in liver cirrhosis. An epidemiologic study", Gastroenterology, 85, pp.141~145 (1983)
Villa E, "Susceptibility of chronic symptomless HBsAg carriers to ethanolinduced hepatic damage", Lancet, 2, pp.1243~1244 (1982)
Trichopoulos D, "Hepatocellular carcinoma risk factors and disease burden in a European cohort : a nested case-control study", J Natl Cancer Inst, 103, pp.1686~1695 (2011)
Jee SH, "Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea", J Natl Cancer Inst, 96, pp.1851~1856 (2004)
Yu MW, "Influence of metabolic risk factors on risk of hepatocellular carcinoma and liverrelated death in men with chronic hepatitis B : a large cohort study", Gastroenterology, 153, pp.1006~1017 (2017)[DOI]
Wong GL, "Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations", Aliment Pharmacol Ther, 39, pp.883~893 (2014)
Chan AW, "Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B", J Gastroenterol Hepatol, 32, pp.667~676 (2017)
Kim JH, "Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients", J Gastroenterol Hepatol, 32, pp.1100~1106 (2017)
Kim NH, "Effect of metabolic syndrome on the clinical outcomes of chronic hepatitis B patients with nucleos(t)ide analogues treatment", Dig Dis Sci, 63, pp.2792~2799 (2018)
Lai CL, "Significance of isolated anti-HBc seropositivity by ELISA : implications and the role of radioimmunoassay", J Med Virol, 36, pp.180~183 (1992)
Sánchez-Quijano A, "Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity", J Hepatol, 17, pp.288~293 (1993)
Raimondo G, "Occult hepatitis B virus in liver tissue of individuals without hepatic disease", J Hepatol, 48, pp.743~746 (2008)
Said ZN, "An overview of occult hepatitis B virus infection", World J Gastroenterol, 17, pp.1927~1938 (2011)
Moon HW, "Laboratory characteristics of recent hepatitis A in Korea : ongoing epidemiological shift", World J Gastroenterol, 16, pp.1115~1118 (2010)
Jacobsen KH, "Declining hepatitis A seroprevalence : a global review and analysis", Epidemiol Infect, 132, pp.1005~1022 (2004)
송현주, "Emerging Need for Vaccination against Hepatitis A Virus in Patients with Chronic Liver Disease in Korea", Journal of Korean Medical Science, 22(2), pp.218~222 (2007), 대한의학회
Yoon EL, "Current status and strategies for the control of viral hepatitis A in Korea", Clin Mol Hepatol, 23, pp.196~204 (2017)
European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, "World Health Organization", WHO, 38~ (2015)
Perrillo RP, "Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B", Hepatology, 36, pp.186~194 (2002)
Prati D, "Updated definitions of healthy ranges for serum alanine aminotransferase levels", Ann Intern Med, 137, pp.1~10 (2002)
Shim JJ, "Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B : a large national cohort study", Liver Int, 38, pp.1751~1759 (2018)
Kariv R, "Reevaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study", Liver Int, 26, pp.445~450 (2006)
Pawlotsky JM, "Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics", J Hepatol, 39(Suppl 1), pp.S31~S35 (2003)
Chu CM, "Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B : a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline", J Hepatol, 43, pp.411~417 (2005)
Sumi H, "Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease", Hepatology, 37, pp.19~26 (2003)
Yu MW, "Hepatitis B virus genotype and DNA level and hepatocellular carcinoma : a prospective study in men", J Natl Cancer Inst, 97, pp.265~272 (2005)
Lin CL, "Natural history of acute and chronic hepatitis B : the role of HBV genotypes and mutants", Best Pract Res Clin Gastroenterol, 31, pp.249~255 (2017)
Kao JH, "Hepatitis B genotypes and the response to interferon therapy", J Hepatol, 33, pp.998~1002 (2000)
Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States : 2008 update", Clin Gastroenterol Hepatol, 6, pp.1315~1341 (2008)[DOI]
Cornberg M, "The role of quantitative hepatitis B surface antigen revisited", J Hepatol, 66, pp.398~411 (2017)
Nguyen T, "Hepatitis B surface antigen levels during the natural history of chronic hepatitis B : a perspective on Asia", J Hepatol, 52, pp.508~513 (2010)
Suh SJ, "Clinical implications of the titer of serum hepatitis B surface antigen during the natural history of hepatitis B virus infection", J Med Virol, 86, pp.117~123 (2014)
Liu J, "Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression", Hepatology, 64, pp.381~389 (2016)
Park H, "Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers", Liver Int, 32, pp.796~802 (2012)
Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149 (2012)[DOI]
Sonneveld MJ, "Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels", Hepatology, 58, pp.872~880 (2013)
Chang ML, "Systematic review : cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B", Aliment Pharmacol Ther, 42, pp.243~257 (2015)
이한아, "Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B", Clinical and Molecular Hepatology, 22(3), pp.382~389 (2016), 대한간학회
Lai M, "The clinical significance of persistently normal ALT in chronic hepatitis B infection", J Hepatol, 47, pp.760~767 (2007)
Lee S, "Non-invasive diagnosis of hepatitis B virus-related cirrhosis", World J Gastroenterol, 20, pp.445~459 (2014)
Parikh P, "Fibrosis assessment in patients with chronic hepatitis B virus(HBV)infection", Ann Transl Med, 5, pp.40~ (2017)
Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
Jin W, "Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis : a leading meta-analysis", BMC Gastroenterol, 12, pp.14~ (2012)
Xiao G, "Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection : a systemic review and meta-analysis", Hepatology, 61, pp.292~302 (2015)
Vallet-Pichard A, "FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
Kim BK, "Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients", Liver Int, 30, pp.546~553 (2010)
Li Y, "The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis : a meta-analysis", PLoS One, 9, pp.e105728~ (2014)
Wong GL, "Update of liver fibrosis and steatosis with transient elastography(Fibroscan)", Gastroenterol Rep(Oxf), 1, pp.19~26 (2013)
Lucidarme D, "Factors of accuracy of transient elastography(fibroscan)for the diagnosis of liver fibrosis in chronic hepatitis C", Hepatology, 49, pp.1083~1089 (2009)
Myers RP, "Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy", Liver Int, 30, pp.1471~1480 (2010)
Castera L, "Non-invasive evaluation of liver fibrosis using transient elastography", J Hepatol, 48, pp.835~847 (2008)
Sandrin L, "Transient elastography : a new noninvasive method for assessment of hepatic fibrosis", Ultrasound Med Biol, 29, pp.1705~1713 (2003)
Castera L, "Biopsy and non-invasive methods for the diagnosis of liver fibrosis : does it take two to tango", Gut, 59, pp.861~866 (2010)
Castera L, "Noninvasive methods to assess liver disease in patients with hepatitis B or C", Gastroenterology, 142, pp.1293~1302 (2012)
Chon YE, "Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B : a meta-analysis", PLoS One, 7, pp.e44930~ (2012)
Zhu X, "Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy", AST platelet ratio index and FIB-4 in patients with chronic HBV infection, 2011, pp.56, 2742~2749
Chang W, "Liver fibrosis staging with MR elastography : comparison of diagnostic performance between patients with chronic hepatitis B and those with other etiologic causes", Radiology, 280, pp.88~97 (2016)
Morisaka H, "Magnetic resonance elastography is as accurate as liver biopsy for liver fibrosis staging", J Magn Reson Imaging, 47, pp.1268~1275 (2018)
Bohte AE, "Non-invasive evaluation of liver fibrosis : a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C", Eur Radiol, 24, pp.638~648 (2014)
Ichikawa S, "Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis", Magn Reson Imaging, 33, pp.26~30 (2015)
Toguchi M, "Magnetic resonance elastography in the assessment of hepatic fibrosis: a study comparing transient elastography and histological data in the same patients", Abdom Radiol(NY), 42, pp.1659~1666 (2017)
Chen J, "Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity", Radiology, 283, pp.418~428 (2017)
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
Han KH, "Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months : a 15-year prospective study", J Clin Gastroenterol, 47, pp.538~544 (2013)
Kim HY, "Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area", Aliment Pharmacol Ther, 47, pp.1490~1501 (2018)
Kim WR, "Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B", Cancer, 121, pp.3631~3638 (2015)
Liaw YF, "Tenofovir disoproxil fumarate(TDF), emtricitabine", TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, 2011, pp.53, 62~72
Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label followup study", Lancet, 381, pp.468~475 (2013)
Matsumoto A, "Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B : a multicenter retrospective study of 2795 patients", Hepatol Res, 32, pp.173~184 (2005)
Shim JH, "Efficacy of entecavir in treatment-naïve patients with hepatitis B virusrelated decompensated cirrhosis", J Hepatol, 52, pp.176~182 (2010)
Yuen MF, "Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease", Antivir Ther, 12, pp.1295~1303 (2007)
Calvaruso V, "Fibrosis in chronic viral hepatitis", Best Pract Res Clin Gastroenterol, 25, pp.219~230 (2011)
Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B : clinical outcomes and durability", Gut, 63, pp.1325~1332 (2014)
Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults : a systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
Tang LSY, "Chronic hepatitis B infection : a review", JAMA, 319, pp.1802~1813 (2018)
Andreani T, "Chronic hepatitis B virus carriers in the immunotolerant phase of infection : histologic findings and outcome", Clin Gastroenterol Hepatol, 5, pp.636~641 (2007)
Grace Lai-Hung Wong, "Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend", Clinical and Molecular Hepatology, 24(2), pp.108~113 (2018), 대한간학회
Kim GA, "High risk of hepatocellular carcinoma and death in patients with immunetolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)
신동현, "A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels", Gut and Liver, 11(4), pp.528~534 (2017), 거트앤리버 소화기연관학회협의회
Park JY, "High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels", J Viral Hepat, 15, pp.615~621 (2008)
Chan HL, "Effects of tenofovir disoproxil fumarate in hepatitis B e antigenpositive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA", Gastroenterology, 146, pp.1240~1248 (2014)
Wong VW, "Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients", J Clin Gastroenterol, 52, pp.347~352 (2018)
Chang Y, "Nucleos(t)ide analogue treatment for patients with hepatitis B virus(HBV)e antigen-positive chronic HBV genotype C infection : a nationwide, multicenter, retrospective study", J Infect Dis, 216, pp.1407~1414 (2017)
Cho JY, "Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease", Gut, 63, pp.1943~1950 (2014)
Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virusendemic population", Hepatology, 66, pp.1454~1463 (2017)
Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)
Kwo PY, "ACG Clinical Guideline : evaluation of abnormal liver chemistries", Am J Gastroenterol, 112, pp.18~35 (2017)
Lee JK, "Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology", Hepatology, 51, pp.1577~1583 (2010)
Won Gil Chung, "Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection", Clinical and Molecular Hepatology, 18(2), pp.195~202 (2012), 대한간학회
Chao DT, "Systematic review with meta-analysis : the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU", L and significant hepatic fibrosis, 2014, pp.39, 349~358
Chen CF, "Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma", Gastroenterology, 141, pp.1240~1248 (2011)
Yuen MF, "Prognostic determinants for chronic hepatitis B in Asians : therapeutic implications", Gut, 54, pp.1610~1614 (2005)
Park HN, "Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease", Liver Int, 32, pp.937~944 (2012)
Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
Hadziyannis SJ, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B", N Engl J Med, 348, pp.800~807 (2003)
Lai CL, "Telbivudine versus lamivudine in patients with chronic hepatitis B", N Engl J Med, 357, pp.2576~2588 (2007)
Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
Marcellin P, "Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B", N Engl J Med, 348, pp.808~816 (2003)
Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
Rockey DC, "Liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines : non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
송병철, "Is it necessary to delay antiviral therapy for 3.6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?", Clinical and Molecular Hepatology, 20(4), pp.355~360 (2014), 대한간학회
Kim HS, "Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B", Gastroenterology, 136, pp.505~512 (2009)
Huang KW, "Efficacy and safety of lamivudine versus entecavir for treating chronic hepatitis B virus-related acute exacerbation and acute-on-chronic liver failure : a systematic review and meta-analysis", J Clin Gastroenterol, 51, pp.539~547 (2017)
Tsai WL, "Chronic hepatitis B with spontaneous severe acute exacerbation", Int J Mol Sci, 16, pp.28126~28145 (2015)
Chen CH, "Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants", J Hepatol, 41, pp.454~461 (2004)
Kim KH, "Defining virologic relapse in chronic hepatitis B", Dig Dis Sci, 56, pp.2432~2438 (2011)
Shih CA, "Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis", PLoS One, 10, pp.e0132426~ (2015)
Garg H, "Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure", Hepatology, 53, pp.774~780 (2011)
Tsai WL, "Early entecavir treatment for chronic hepatitis B with severe acute exacerbation", Antimicrob Agents Chemother, 58, pp.1918~1921 (2014)
Wong VW, "Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B", J Hepatol, 54, pp.236~242 (2011)
Jung Min Ha, "Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure", Clinical and Molecular Hepatology, 21(3), pp.232~241 (2015), 대한간학회
Park JG, "Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B", Dig Liver Dis, 50, pp.163~167 (2018)
Chen CH, "lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation", J Hepatol, 60, pp.1127~1134 (2014)
Yasui S, "Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B", J Viral Hepat, 22, pp.94~102 (2015)
Yue-Meng W, "The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure", Hepatol Int, 10, pp.462~469 (2016)
Ahn JM, "Prediction of clinical outcomes in hepatitis B e antigen negative chronic hepatitis B patients with elevated hepatitis B virus DNA levels", PLoS One, 10, pp.e0144777~ (2015)
Paik N, "Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia", Liver Int, 38, pp.68~75 (2018)
de Niet A, "Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load : a randomised controlled, open-label trial", Lancet Gastroenterol Hepatol, 2, pp.576~584 (2017)
Chang TT, "Long term entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
이정규, "Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels", Journal of Korean Medical Science, 30(11), pp.1618~1624 (2015), 대한의학회
Kim JH, "Lowlevel viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment", Hepatology, 66, pp.335~343 (2017)
Sinn DH, "Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load", Hepatology, 62, pp.694~701 (2015)
Cho YY, "Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients", J Viral Hepat, 25, pp.1161~1171 (2018)
Suk KT, "Revision and update on clinical practice guideline for liver cirrhosis", Korean J Hepatol, 18, pp.1~21 (2012)
Jang JW, "Longterm effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis", Hepatology, 61, pp.1809~1820 (2015)
Fontana RJ, "Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy", Gastroenterology, 123, pp.719~727 (2002)
Perrillo R, "Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus", Gastroenterology, 109, pp.908~916 (1995)
Kim YJ, "The change of the quantitative HBsAg level during the natural course of chronic hepatitis B", Liver Int, 31, pp.817~823 (2011)
Wang L, "Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection", Hepatol Int, 10, pp.133~138 (2016)
Yim SY, "Role of hepatitis B surface antigen(HBsAg)in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus", J Clin Gastroenterol, 48, pp.166~171 (2014)
Koumbi L, "Current and future antiviral drug therapies of hepatitis B chronic infection", World J Hepatol, 7, pp.1030~1040 (2015)
Lau GK, "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
Marcellin P, "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 351, pp.1206~1217 (2004)
Qiu K, "Systematic review with meta-analysis : combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance", Aliment Pharmacol Ther, 47, pp.1340~1348 (2018)
Viganò M, "Treatment of hepatitis B: is there still a role for interferon?", Liver Int, 38(Suppl 1), pp.79~83 (2018)
Janssen HL, "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B : a randomised trial", Lancet, 365, pp.123~129 (2005)
Li WC, "Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion : a meta-analysis of controlled clinical trials", BMC Infect Dis, 11, pp.165~ (2011)
Zoulim F, "Hepatitis B virus resistance to nucleos(t)ide analogues", Gastroenterology, 137, pp.1593~1608 (2009)
An J, "Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA : a randomized trial", BMC Gastroenterol, 17, pp.15~ (2017)
Agarwal K, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection", J Hepatol, 68, pp.672~681 (2018)
Chan HL, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.185~195 (2016)
Buti M, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.196~206 (2016)
Seto WK, "Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection", Clin Gastroenterol Hepatol (2018)[DOI]
Yuen MF, "A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B", Antivir Ther, 11, pp.977~983 (2006)
Yuen MF, "Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B(CHB), in healthy adult subjects, CHB patients, and mice", Antimicrob Agents Chemother, 53, pp.1779~1785 (2009)
"J Hepatol", 2017, S88~S89
Lam YF, "Seven-year treatment outcome of entecavir in a real-world cohort : effects on clinical parameters, HBsAg and HBcrAg levels", Clin Transl Gastroenterol, 8, pp.e125~ (2017)
Hou J, "Prospective, randomized assessment of HBV-associated and other clinical outcome events during long-term therapy with entecavir or other HBV nucleos(t)ide analogues in patients with chronic HBV infection", Hepatology, 66(S1), pp.12A~13A (2017)
Liu Y, "No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg-patients with chronic hepatitis B after 8 years of treatment", J Viral Hepat, 24, pp.68~74 (2017)
Konerman MA, "Interferon treatment for hepatitis B", Clin Liver Dis, 20, pp.645~665 (2016)
Cooksley WG, "Peginterferon alpha-2a(40 kDa) : an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B", J Viral Hepat, 10, pp.298~305 (2003)
Chan HL, "A randomized, controlled trial of combination therapy for chronic hepatitis B : comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone", Ann Intern Med, 142, pp.240~250 (2005)
Buster EH, "Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b", Gastroenterology, 135, pp.459~467 (2008)
Liaw YF, "Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C", Hepatology, 54, pp.1591~1599 (2011)
조주연, "Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response", The Korean Journal of Internal Medicine, 32(4), pp.636~646 (2017), 대한내과학회[DOI]
Cai S, "Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs", Infect Drug Resist, 11, pp.469~477 (2018)
Song G, "Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients", J Med Virol, 89, pp.463~468 (2017)
Yang J, "HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients", J Transl Med, 12, pp.183~ (2014)
You H, "Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles", J Viral Hepat, 16, pp.876~882 (2009)
Zeuzem S, "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B", J Hepatol, 51, pp.11~20 (2009)
Gane EJ, "The Roadmap concept : using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B", Hepatol Int, 2, pp.304~307 (2008)
Chan HL, "Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B", Aliment Pharmacol Ther, 25, pp.891~898 (2007)
Yuen MF, "Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response", Hepatology, 46, pp.1695~1703 (2007)
Gish RG, "Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B", J Viral Hepat, 17, pp.16~22 (2010)
Marcellin P, "Kinetics of hepatitis B surface antigen loss in patients with HBeAgpositive chronic hepatitis B treated with tenofovir disoproxil fumarate", J Hepatol, 61, pp.1228~1237 (2014)
Fung S, "Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load(≥ 9 log10 copies", ml), 2015, pp.35, 422~428
Buster EH, "Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa", Gastroenterology, 137, pp.2002~2009 (2009)
Kong LN, "Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients : a meta-analysis", J Gastroenterol Hepatol, 29, pp.1387~1395 (2014)
Chan HLY, "A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B", Aliment Pharmacol Ther, 48, pp.547~555 (2018)
Goulis I, "On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients", Liver Int, 35, pp.1540~1548 (2015)
Moucari R, "Early serum HBsAg drop : a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients", Hepatology, 49, pp.1151~1157 (2009)
Piratvisuth T, "Hepatitis B surface antigen : association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients", Hepatol Int, 7, pp.429~436 (2013)
Locarnini S, "Cellular and virological mechanisms of HBV drug resistance", J Hepatol, 44, pp.422~431 (2006)
Yuan HJ, "The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B", J Viral Hepat, 12, pp.373~379 (2005)
Jung YK, "Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir", J Clin Gastroenterol, 44, pp.653~657 (2010)
Manesis EK, "Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B : a clue from serum HBsAg levels", Antivir Ther, 12, pp.73~82 (2007)
Reijnders JG, "Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir", J Hepatol, 54, pp.449~454 (2011)
Gramenzi A, "Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients", J Viral Hepat, 18, pp.e468~ (2011)[DOI]
Kwon JH, "Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B", J Viral Hepat, 19, pp.e41~e47 (2012)
Zoulim F, "Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study", J Hepatol, 62, pp.56~63 (2015)
Seto WK, "Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy", Hepatology, 58, pp.923~931 (2013)
Chen CH, "Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 13, pp.1984~1992 (2015)[DOI]
Chen CH, "The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment", J Hepatol, 61, pp.515~522 (2014)
Hsu YC, "Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in E antigen-negative patients", Clin Gastroenterol Hepatol, 14, pp.1490~1498 (2016)[DOI]
Wang CC, "Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg", Am J Gastroenterol, 111, pp.1286~1294 (2016)
Kim HS, "Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization", Antivir Ther, 10, pp.441~449 (2005)
Lee JM, "Rescue monotherapy in lamivudine-resistant hepatitis B e antigenpositive chronic hepatitis B : adefovir versus entecavir", Antivir Ther, 14, pp.705~712 (2009)
Lee JM, "Longterm adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B", Antivir Ther, 15, pp.235~241 (2010)
박삼엘, "Adefovir-induced Fanconi syndrome associated with osteomalacia", Clinical and Molecular Hepatology, 24(3), pp.339~344 (2018), 대한간학회
Samarkos M, "Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B", J Gastrointestin Liver Dis, 23, pp.342~ (2014)
Fleischer RD, "Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B", J Hepatol, 51, pp.787~791 (2009)
Kim BK, "Clevudine myopathy in patients with chronic hepatitis B", J Hepatol, 51, pp.829~834 (2009)
Tak WY, "Clinical, biochemical, and pathological characteristics of clevudineassociated myopathy", J Hepatol, 53, pp.261~266 (2010)
Brunetto MR, "Hepatitis B virus surface antigen levels : a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B", Hepatology, 49, pp.1141~1150 (2009)
Marcellin P, "Hepatitis B surface antigen levels : association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigennegative patients", Hepatol Int, 7, pp.88~97 (2013)
Chen X, "Extended peginterferon alfa-2a(Pegasys)therapy in Chinese patients with HBeAgnegative chronic hepatitis B", J Med Virol, 86, pp.1705~1713 (2014)
Lampertico P, "Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B", Gut, 62, pp.290~298 (2013)
Kang HS, "Healthy range for serum ALT and the clinical significance of"unhealthy"normal ALT levels in the Korean population", J Gastroenterol Hepatol, 26, pp.292~299 (2011)
Fattovich G, "Long-term outcome of chronic hepatitis B in Caucasian patients : mortality after 25 years", Gut, 57, pp.84~90 (2008)
Fattovich G, "Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis : a cohort study of 297patients", Am J Gastroenterol, 97, pp.2886~2895 (2002)
Mommeja-Marin H, "Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection : analysis and review of the literature", Hepatology, 37, pp.1309~1319 (2003)
Hadziyannis SJ, "Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir", Gastroenterology, 143, pp.629~636 (2012)[DOI]
Papatheodoridis G, "Discontinuation of oral antivirals in chronic hepatitis B : a systematic review", Hepatology, 63, pp.1481~1492 (2016)
Berg T, "Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients-FINITE study", J Hepatol, 67, pp.918~924 (2017)
Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
Jeng WJ, "Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients", Hepatology, 58, pp.1888~1896 (2013)
김영집, "Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients", Clinical and Molecular Hepatology, 19(3), pp.300~304 (2013), 대한간학회[DOI]
Seto WK, "Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B : a multicentre prospective study", Gut, 64, pp.667~672 (2015)
Fattovich G, "Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B", Hepatology, 6, pp.167~172 (1986)
Yang HI, "Hepatitis B e antigen and the risk of hepatocellular carcinoma", N Engl J Med, 347, pp.168~174 (2002)
Niederau C, "Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B", N Engl J Med, 334, pp.1422~1427 (1996)
Reijnders JG, "Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B", Gastroenterology, 139, pp.491~498 (2010)
Song BC, "Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea", Hepatology, 32(4), pp.803~806 (2000)
Byun KS, "Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy", J Gastroenterol Hepatol, 20, pp.1838~1842 (2005)
Lee HW, "Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B", Hepatology, 51, pp.415~421 (2010)
Chan HL, "Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response", Clin Gastroenterol Hepatol, 5, pp.1462~1468 (2007)
Kim JH, "HBsAg seroclearance in chronic hepatitis B : implications for hepatocellular carcinoma", J Clin Gastroenterol, 45, pp.64~68 (2011)
Yip TC, "Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients", J Hepatol (2017)[DOI]
Chevaliez S, "Longterm hepatitis B surface antigen(HBsAg)kinetics during nucleoside", nucleotide analogue therapy : finite treatment duration unlikely, 2013, pp.58, 676~683
Seto WK, "Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment", J Hepatol, 59, pp.709~716 (2013)
Fung J, "Long term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B eantigen seroclearance", Hepatology, 68, pp.462~472 (2018)
Kim GA, "Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients : a need for surveillance", J Hepatol, 62, pp.1092~1099 (2015)
Nafa S, "Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B", Hepatology, 32, pp.1078~1088 (2000)
Zoulim F, "Management and prevention of drug resistance in chronic hepatitis B", Liver Int, 29(Suppl 1), pp.108~115 (2009)
Lai CL, "Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B", Clin Infect Dis, 36, pp.687~696 (2003)
Melegari M, "Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective", Hepatology, 27, pp.628~633 (1998)
Tenney DJ, "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine", Antimicrob Agents Chemother, 48, pp.3498~3507 (2004)
Bartholomeusz A, "Antiviral drug resistance : clinical consequences and molecular aspects", Semin Liver Dis, 26, pp.162~170 (2006)
Lok AS, "Longterm safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
Lok AS, "Antiviral drug-resistant HBV : standardization of nomenclature and assays and recommendations for management", Hepatology, 46, pp.254~265 (2007)
Gish RG, "Safety and antiviral activity of emtricitabine(FTC)for the treatment of chronic hepatitis B infection : a two-year study", J Hepatol, 43, pp.60~66 (2005)
Stuyver LJ, "Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region", Hepatology, 33, pp.751~757 (2001)
Liaw YF, "2-Year GLOBE trial results : telbivudine is superior to lamivudine in patients with chronic hepatitis B", Gastroenterology, 136, pp.486~495 (2009)
고경현, "라미부딘 치료 후 클레부딘으로 전환한 만성 B형간염 환자에서 발생된 클레부딘 내성 1예: 연관 염기서열 분석", 대한소화기학회지, 52(5), pp.325~328 (2008), 대한소화기학회
Yoon EL, "Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection : two-year follow-up data", J Clin Gastroenterol, 45, pp.893~899 (2011)
Locarnini S, "Molecular virology and the development of resistant mutants : implications for therapy", Semin Liver Dis, 25(Suppl 1), pp.9~19 (2005)
Qi X, "In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents", Antivir Ther, 12, pp.355~362 (2007)
Tenney DJ, "Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present", Antimicrob Agents Chemother, 51, pp.902~911 (2007)
Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
Lee JH, "Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B patients without detectable lamivudine resistance", Antimicrob Agents Chemother, 58, pp.1730~1737 (2014)
Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
Villeneuve JP, "Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient", J Hepatol, 39, pp.1085~1089 (2003)
Villet S, "Impact of hepatitis B virus rtA181V", T mutants on hepatitis B treatment failure, 2008, pp.48, 747~755
Lampertico P, "Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients", Gastroenterology, 133, pp.1445~1451 (2007)
Delaney WE 4th, "Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus", Antimicrob Agents Chemother, 50, pp.2471~2477 (2006)
Sheldon J, "Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir", Antivir Ther, 10, pp.727~734 (2005)
Amini-Bavil-Olyaee S, "The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains", Hepatology, 49, pp.1158~1165 (2009)
Shirvani-Dastgerdi E, "Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDFETV combination therapy", J Hepatol, 67, pp.246~254 (2017)
Park ES, "Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients", J Hepatol, 70, pp.1093~1102 (2019)
Ahn SH, "Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection", Clin Gastroenterol Hepatol (2018)[DOI]
Yuen MF, "Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study", J Hepatol, 62, pp.526~532 (2015)
Yim HJ, "Evolution of multi-drug resistant hepatitis B virus during sequential therapy", Hepatology, 44, pp.703~712 (2006)
Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", Hepatology, 43, pp.1385~1391 (2006)
Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil", Gut, 55, pp.1488~1495 (2006)
임형준, "약제 내성 B형간염에 대한 대처", 대한소화기학회지, 51(6), pp.346~359 (2008), 대한소화기학회
Fung S, "Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 146, pp.980~988 (2014)
Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure : results of a randomised trial", Gut, 65, pp.852~860 (2016)
Lee S, "Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance", J Viral Hepat, 24, pp.141~147 (2017)
Berg T, "Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients", J Hepatol, 60, pp.715~722 (2014)
Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure : results of a randomised trial", Gut, 65, pp.1042~1051 (2016)
Lim YS, "Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B : 3-year trial", Hepatology, 66, pp.772~783 (2017)
정고은, "Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)idenaïve patients", Clinical and Molecular Hepatology, 23(1), pp.66~73 (2017), 대한간학회[DOI]
Yim HJ, "Options for the management of antiviral resistance during hepatitis B therapy : reflections on battles over a decade", Clin Mol Hepatol, 19, pp.195~209 (2013)
Park JY, "Entecavir plus tenofovir combination therapy in patients with multidrugresistant chronic hepatitis B : results of a multicentre, prospective study", Liver Int, 36, pp.1108~1115 (2016)
Yim HJ, "Tenofovir-based combination therapy or monotherapy for multi-drug resistant chronic hepatitis B; real world data from multicenter cohort study", Hepatology, 66, pp.12A~ (2017)
Lee JH, "Identification of a triple mutation that confers tenofovir resistance in chronic hepatitis B patients", Hepatology, 66, pp.69A~70A (2017)
Heo J, "A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine", Antivir Ther, 17, pp.1563~1570 (2012)
Yim HJ, "Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir : a randomized controlled trial", J Viral Hepat, 25, pp.1321~1330 (2018)
Chen J, "Comparison of the efficacy of tenofovir versus tenofovir plus entecavir in the treatment of chronic hepatitis B in patients with poor efficacy of entecavir : a systematic review and meta-analysis", Clin Ther, 39, pp.1870~1880 (2017)
Jeong DI, "Clinical course of partial virologic response with prolonged tenofovir therapy in nuclos(t)ides-naïve patients with chronic hepatitis B", Dig Dis Sci, 62, pp.2908~2914 (2017)
Lee HW, "Longterm efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic HBV infection", Clin Gastroenterol Hepatol (2018)[DOI]
Kim DY, "Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance", J Med Virol, 90, pp.497~502 (2018)
Nagata N, "Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B", BMC Gastroenterol, 16, pp.38~ (2016)
Ning Q, "Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B : a randomised open-label trial(OSST trial)", J Hepatol, 61, pp.777~784 (2014)
Hu P, "HBsAg loss with Peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog : new switch study", J Clin Transl Hepatol, 6, pp.25~34 (2018)
Xie Q, "A randomized, open-label clinical study of combined pegylated interferon Alfa-2a(40KD)and entecavir treatment for hepatitis B"e"antigen-positive chronic hepatitis B", Clin Infect Dis, 59, pp.1714~1723 (2014)
Li GJ, "Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen(HBeAg)seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment", Antimicrob Agents Chemother, 59, pp.4121~4128 (2015)
Zhang W, "The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: a review of published literature", J Viral Hepat, 24, pp.618~623 (2017)
Bourlière M, "Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigennegative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA : a randomised, controlled, open-label trial", Lancet Gastroenterol Hepatol, 2, pp.177~188 (2017)
Lee JH, "Entecavir plus pegylated interferon alfa-2a and sequential HBV vaccination increases the chance of HBsAg-seroclearance: a results from randomized controlled E+VIP Trial", Clin Mol Hepatol, 24(Suppl 3), pp.2~ (2018)
Rijckborst V, "Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a", J Hepatol, 56, pp.1006~1011 (2012)
Wu CY, "Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection", JAMA, 308, pp.1906~1914 (2012)
Huang G, "Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels : a randomized controlled trial", Ann Surg, 268, pp.943~954 (2018)
Wong JS, "Meta-analysis : the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma", Aliment Pharmacol Ther, 33, pp.1104~1112 (2011)
Cho H, "Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals", J Viral Hepat, 25, pp.707~717 (2018)
Chen LT, "Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection", Ann Surg, 255, pp.8~17 (2012)
Kubo S, "Reactivation of viral replication after liver resection in patients infected with hepatitis B virus", Ann Surg, 233, pp.139~145 (2001)
Huang L, "Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy : a randomized controlled trial", J Viral Hepat, 20, pp.336~342 (2013)
Dan JQ, "Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma : a retrospective study", Eur J Surg Oncol, 39, pp.865~872 (2013)
Yoshida H, "Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma", Hepatol Int, 2, pp.89~94 (2008)
Lao XM, "Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma", Liver Int, 33, pp.595~604 (2013)
Lao XM, "Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma", Hepatol Res, 41, pp.553~563 (2011)
Firpi RJ, "Management of viral hepatitis in hematologic malignancies", Blood Rev, 22, pp.117~126 (2008)
Jang JW, "A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization", Hepatology, 43, pp.233~240 (2006)
Park JW, "Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma : report of a prospective study", Am J Gastroenterol, 100, pp.2194~2200 (2005)
Yeo W, "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy", Ann Oncol, 15, pp.1661~1666 (2004)
Nagamatsu H, "Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy", Am J Gastroenterol, 99, pp.2369~2375 (2004)
Tamori A, "Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma", Hepatol Res, 26, pp.77~80 (2003)
Kim JH, "Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 69, pp.813~819 (2007)
Jang JW, "Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma", Antivir Ther, 16, pp.969~977 (2011)
Shim JH, "Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area", J Cancer Res Clin Oncol, 135, pp.617~625 (2009)
Suh SJ, "The risk of hepatitis B virus reactivation is considerably high during sorafenib therapy in patients with advanced hepatocellular carcinoma", J Hepatol, 66, pp.S449~S450 (2017)
Loomba R, "Hepatitis B reactivation associated with immune suppressive and biological modifier therapies : current concepts, management strategies, and future directions", Gastroenterology, 152, pp.1297~1309 (2017)
Lampertico P, "Review article : long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients", Aliment Pharmacol Ther, 44, pp.16~34 (2016)
Gracey DM, "Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection", Antivir Ther, 18, pp.945~948 (2013)
Maggi P, "Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis : a longitudinal study", J Antimicrob Chemother, 70, pp.1150~1154 (2015)
López-Alcorocho JM, "Prevalence of hepatitis B, hepatitis C, GB virus C", hepatitis G and TT viruses in predialysis and hemodialysis patients, 2001, pp.63, 103~107
Gwak GY, "Occult hepatitis B virus infection in chronic hemodialysis patients in Korea", Hepatogastroenterology, 55, pp.1721~1724 (2008)
Minuk GY, "Occult hepatitis B virus infection in a North American adult hemodialysis patient population", Hepatology, 40, pp.1072~1077 (2004)
Burdick RA, "Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents : the DOPPS", Kidney Int, 63, pp.2222~2229 (2003)
Johnson DW, "Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries : analysis of registry data", Nephrol Dial Transplant, 24, pp.1598~1603 (2009)
Finelli L, "National surveillance of dialysis-associated diseases in the United States, 2002", Semin Dial, 18, pp.52~61 (2005)
Hu TH, "Chronic hepatitis B patient treated with Tenofovir (TDF) may experience increased risks of orthopedic disorders and renal deficits compared to those treated with Enetecavir (ETV)", Hepatology, 68(S1), pp.264A~ (2018)
Lai CL, "Phase IIb multicentred randomised trial of besifovir(LB80380)versus entecavir in Asian patients with chronic hepatitis B", Gut, 63, pp.996~1004 (2014)
Gane E, "Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use", J Hepatol, 68(S1), pp.S87~ (2018)
Yuki N, "Long-term histologic and virologic outcomes of acute self-limited hepatitis B", Hepatology, 37, pp.1172~1179 (2003)
Shiffman ML, "Management of acute hepatitis B", Clin Liver Dis, 14, pp.75~91 (2010)
Lampertico P, "Optimal management of hepatitis B virus infection - EASL Special Conference", J Hepatol, 63, pp.1238~1253 (2015)
European Association for the Study of the Liver, "EASL Clinical Practical Guidelines on the management of acute(fulminant)liver failure", J Hepatol, 66, pp.1047~1081 (2017)
Böcher WO, "Regulation of the neutralizing antihepatitis B surface(HBs)antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus(HBV)infection", Clin Exp Immunol, 105, pp.52~58 (1996)
Mantzoukis K, "Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis", Cochrane Database Syst Rev, 3, pp.CD011645~ (2017)
Kumar M, "A randomized controlled trial of lamivudine to treat acute hepatitis B", Hepatology, 45, pp.97~101 (2007)
Yu JW, "The study of efficacy of lamivudine in patients with severe acute hepatitis B", Dig Dis Sci, 55, pp.775~783 (2010)
Jochum C, "Treatment of fulminant acute Hepatitis B with nucles(t)id analogues is safe and does not lead to secondary chronification of Hepatitis B", Z Gastroenterol, 54, pp.1306~1311 (2016)
Tillmann HL, "Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience", J Viral Hepat, 13, pp.256~263 (2006)
Miyake Y, "Lamivudine treatment improves the prognosis of fulminant hepatitis B", Intern Med, 47, pp.1293~1299 (2008)
Streinu-Cercel A, "Treatment with lamivudine and entecavir in severe acute hepatitis B", Indian J Med Microbiol, 34, pp.166~172 (2016)
Gerada J, "Tenofovir as rescue therapy following clinical failure to Lamivudine in severe acute hepatitis B", Mediterr J Hematol Infect Dis, 5, pp.e2013035~ (2013)
Gupta S, "Spontaneous reactivation in chronic hepatitis B : patterns and natural history", J Clin Gastroenterol, 12, pp.562~568 (1990)
Lok AS, "Chronic hepatitis B : update of recommendations", Hepatology, 39, pp.857~861 (2004)
Tanaka Y, "Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus", Liver, 10, pp.6~10 (1990)
Koo YX, "Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy", Cancer, 116, pp.115~121 (2010)
Koo YX, "Risk of hepatitis B virus(HBV)reactivation in hepatitis B surface antigen negative", hepatitis B core antibody positive patients receiving rituximabcontaining combination chemotherapy without routine antiviral prophylaxis, 2011, pp.90, 1219~1223
Yeo W, "Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy", Hepatology, 43, pp.209~220 (2006)
Hwang JP, "Management of patients with hepatitis B who require immunosuppressive therapy", Nat Rev Gastroenterol Hepatol, 11, pp.209~219 (2014)
Bessone F, "Management of hepatitis B reactivation in immunosuppressed patients : an update on current recommendations", World J Hepatol, 8, pp.385~394 (2016)
Lok AS, "Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study", Gastroenterology, 100, pp.182~188 (1991)
Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy : a prospective study of 626 patients with identification of risk factors", J Med Virol, 62, pp.299~307 (2000)
Loomba R, "Systematic review : the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy", Ann Intern Med, 148, pp.519~528 (2008)
Kwak LW, "Prognostic significance of actual dose intensity in diffuse large-cell lymphoma : results of a tree-structured survival analysis", J Clin Oncol, 8, pp.963~977 (1990)
Bonadonna G, "Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer : the results of 20 years of follow-up", N Engl J Med, 332, pp.901~906 (1995)
Yeo W, "Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy : a prospective study", J Med Virol, 70, pp.553~561 (2003)
Jang JW, "Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy", World J Gastroenterol, 20, pp.7675~7685 (2014)
Perrillo RP, "American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.221~244 (2015)
Reddy KR, "American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.215~219 (2015)
Takai S, "Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy", Eur J Haematol, 74, pp.158~165 (2005)
Hsu C, "A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma : a randomized trial", Hepatology, 47, pp.844~853 (2008)
Engels EA, "Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea : a cohort study", Lancet Oncol, 11, pp.827~834 (2010)
Cheng AL, "Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV)reactivation in HBV-carriers with lymphoma", Hepatology, 37, pp.1320~1328 (2003)
Yeo W, "Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab", J Clin Oncol, 27, pp.605~611 (2009)
Dong HJ, "Risk of hepatitis B virus(HBV)reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy : a meta-analysis", J Clin Virol, 57, pp.209~214 (2013)
Chen XQ, "The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy", Med Oncol, 29, pp.1237~1241 (2012)
Zurawska U, "Hepatitis B virus screening before chemotherapy for lymphoma : a cost-effectiveness analysis", J Clin Oncol, 30, pp.3167~3173 (2012)
Buti M, "Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies : the Preblin study", PLoS One, 12, pp.e0184550~ (2017)
Lau GK, "Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation", Hepatology, 36, pp.702~709 (2002)
Sarmati L, "Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper", Clin Microbiol Infect, 23, pp.935~940 (2017)
Chen CY, "Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan", BMC Gastroenterol, 18, pp.6~ (2018)
Chen FW, "Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease", Liver Int, 33, pp.1203~1210 (2013)
김민경, "Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience", The Korean Journal of Internal Medicine, 22(4), pp.237~243 (2007), 대한내과학회
Dai MS, "Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration", Liver Int, 24, pp.540~546 (2004)
Wu YT, "Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy : a systematic review and meta-analysis", PLoS One, 12, pp.e0179680~ (2017)
Xu Z, "Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: a meta-analysis", Eur J Cancer Care(Engl), 27, pp.e12799~ (2018)
El-Sayed MH, "Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies", Hematol J, 4, pp.321~327 (2003)
Yeo W, "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B santigen seropositive cancer patients undergoing cytotoxic chemotherapy", J Clin Oncol, 22, pp.927~934 (2004)
Chung SJ, "Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy", J Rheumatol, 36, pp.2416~2420 (2009)
Esteve M, "Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients : need for primary prophylaxis", Gut, 53, pp.1363~1365 (2004)
Kim YJ, "Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases", J Rheumatol, 37, pp.346~350 (2010)
Lee YH, "Hepatitis B virus reactivation in HBsAgpositive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs", Int J Rheum Dis, 16, pp.527~531 (2013)
Pérez-Alvarez R, "Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases", Medicine(Baltimore), 90, pp.359~371 (2011)
Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", Gastroenterology, 125, pp.1742~1749 (2003)
Saab S, "Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma : a decision analysis model", Hepatology, 46, pp.1049~1056 (2007)
Viganò M, "Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders", Expert Opin Biol Ther, 16, pp.917~926 (2016)
Hui CK, "Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy", Gut, 54, pp.1597~1603 (2005)
Cerva C, "Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor", Clin Microbiol Infect, 22, pp.946.e1~946.e8 (2016)
Liu WP, "Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma", Leuk Lymphoma, 57, pp.1355~1362 (2016)
Nakaya A, "Delayed HBV reactivation in rituximab-containing chemotherapy : how long should we continue anti-virus prophylaxis or monitoring HBV-DNA", Leuk Res, 50, pp.46~49 (2016)
Paul S, "Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy : a meta-analysis", Hepatology, 66, pp.379~388 (2017)
Rossi G, "Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy", Br J Haematol, 115, pp.58~62 (2001)
Li HR, "Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy", J Viral Hepat, 18, pp.877~883 (2011)
Yu S, "Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy : a meta-analysis", Int J Clin Pharm, 38, pp.1035~1043 (2016)
Demetris AJ, "Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection", Am J Pathol, 125, pp.161~172 (1986)
Demetris AJ, "Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations", Am J Pathol, 137, pp.667~676 (1990)
Freeman RB, "Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation", Transplantation, 51, pp.793~797 (1991)
Lake JR, "Liver transplantation for patients with hepatitis B: what have we learned from our results?", Hepatology, 13, pp.796~799 (1991)
O’Grady JG, "Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications", J Hepatol, 14, pp.104~111 (1992)
Rizzetto M, "Liver transplantation in carriers of the HBsAg", J Hepatol, 13, pp.5~7 (1991)
Todo S, "Orthotopic liver transplantation for patients with hepatitis B virusrelated liver disease", Hepatology, 13, pp.619~626 (1991)
Samuel D, "Liver transplantation in European patients with the hepatitis B surface antigen", N Engl J Med, 329, pp.1842~1847 (1993)
Han SH, "An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy", Liver Transpl, 6, pp.741~748 (2000)
Markowitz JS, "Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin", Hepatology, 28, pp.585~589 (1998)
Marzano A, "Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis", J Hepatol, 34, pp.903~910 (2001)
Steinmüller T, "Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease", Hepatology, 35, pp.1528~1535 (2002)
Katz LH, "Prevention of recurrent hepatitis B virus infection after liver transplantation : hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis", Transpl Infect Dis, 12, pp.292~308 (2010)
Loomba R, "Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation : meta-analysis", Clin Gastroenterol Hepatol, 6, pp.696~700 (2008)
Mutimer D, "Lamivudine without HBIg for prevention of graft reinfection by hepatitis B : long-term follow-up", Transplantation, 70, pp.809~815 (2000)
Perrillo RP, "A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B", Hepatology, 33, pp.424~432 (2001)
Gane EJ, "Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates", Liver Transpl, 19, pp.268~274 (2013)
Fung J, "Oral nucleoside", nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B, 2013, pp.108, 942~948
Fung J, "Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation", Gastroenterology, 141, pp.1212~1219 (2011)
Fung J, "Longterm outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation : results up to 8 years", Hepatology, 66, pp.1036~1044 (2017)
Cholongitas E, "High genetic barrier nucleos(t)ide analogue(s)for prophylaxis from hepatitis B virus recurrence after liver transplantation : a systematic review", Am J Transplant, 13, pp.353~362 (2013)
Gane EJ, "Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation", Gastroenterology, 132, pp.931~937 (2007)
Cholongitas E, "New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence", Transpl Int, 27, pp.1022~1028 (2014)
Cholongitas E, "Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation", Transpl Infect Dis, 14, pp.479~487 (2012)
European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Liver transplantation", J Hepatol, 64, pp.433~485 (2016)
Perrillo R, "Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B", Liver Transpl, 19, pp.887~895 (2013)
Fox AN, "The option of HBIG-free prophylaxis against recurrent HBV", J Hepatol, 56, pp.1189~1197 (2012)
Wang P, "Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis", PLoS One, 9, pp.e104480~ (2014)
Fernández I, "Tenofovir", entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients, 2015, pp.17, 695~701
Cholongitas E, "Liver grafts from anti-hepatitis B core positive donors : a systematic review", J Hepatol, 52, pp.272~279 (2010)
Wachs ME, "The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-)organ donors", Transplantation, 59, pp.230~234 (1995)
Prieto M, "De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population", Liver Transpl, 7, pp.51~58 (2001)
Chotiyaputta W, "Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers", Hepatol Int, 4, pp.707~715 (2010)
Avelino-Silva VI, "Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient : is it safe? A systematic review of the literature", Clin Transplant, 24, pp.735~746 (2010)
Saab S, "Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors : a systematic review", Liver Transpl, 16, pp.300~307 (2010)
Lee KW, "Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation", Transplant Proc, 36, pp.2311~2312 (2004)
Takemura N, "Liver transplantation using hepatitis B core antibody-positive grafts : review and university of Tokyo experience", Dig Dis Sci, 52, pp.2472~2477 (2007)
Wright AJ, "Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers : a cost-effectiveness analysis", Am J Transplant, 14, pp.629~634 (2014)
Fontana RJ, "A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation", Liver Transpl, 7, pp.504~510 (2001)
Ben-Ari Z, "Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation", Liver Transpl, 7, pp.113~117 (2001)
Perrillo R, "Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group", Hepatology, 29, pp.1581~1586 (1999)
Ben-Ari Z, "Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis", Transplantation, 68, pp.232~236 (1999)
Neff GW, "Outcomes in liver transplant recipients with hepatitis B virus : resistance and recurrence patterns from a large transplant center over the last decade", Liver Transpl, 10, pp.1372~1378 (2004)
Fornairon S, "The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection", Transplantation, 62, pp.297~299 (1996)
Ahn HJ, "Clinical outcome of renal transplantation in patients with positive pretransplant hepatitis B surface antigen", J Med Virol, 79, pp.1655~1663 (2007)
Cosconea S, "Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection", J Hepatol, 57, pp.55~60 (2012)
Yap DY, "Longterm outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments", Transplantation, 90, pp.325~330 (2010)
Yap DY, "Entecavir treatment in kidney transplant recipients infected with hepatitis B", Clin Transplant, 28, pp.1010~1015 (2014)
Lee J, "Pretransplant hepatitis B viral infection increases risk of death after kidney transplantation:a multicenter cohort study in Korea", Medicine (Baltimore), 95, pp.e3671~ (2016)
Shin HS, "The impact of hepatitis B on heart transplantation : 19 years of national experience in Korea", Ann Transplant, 19, pp.182~187 (2014)
Durante-Mangoni E, "Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients", Transpl Infect Dis, 18, pp.319~325 (2016)
Jeon JW, "Presence of hepatitis B surface antibody in addition to hepatitis B core antibody confers protection against hepatitis B virus infection in hepatitis B surface antigen-negative patients undergoing kidney transplantation", Transplantation, 102, pp.1717~1723 (2018)
Lee J, "Rituximab and hepatitis B reactivation in HBsAg-negative", anti-HBc-positive kidney transplant recipients, 2017, pp.32, 722~729
Masutani K, "Incidence of hepatitis B viral reactivation after kidney transplantation with low-dose rituximab administration", Transplantation, 102, pp.140~145 (2018)
Mahboobi N, "Renal grafts from anti-hepatitis B core-positive donors : a quantitative review of the literature", Transpl Infect Dis, 14, pp.445~451 (2012)
Chamorro C, "Influence of anti-HBc positive organ donor in lung donor selection", Arch Bronconeumol, 48, pp.320~324 (2012)
Huprikar S, "Solid organ transplantation from hepatitis B virus-positive donors : consensus guidelines for recipient management", Am J Transplant, 15, pp.1162~1172 (2015)
Lau GK, "High hepatitis B virus(HBV)DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation", Blood, 99, pp.2324~2330 (2002)
Li J, "Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation", Tumour Biol, 34, pp.1723~1728 (2013)
Shang J, "A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients : a single-institutional experience", Bone Marrow Transplant, 51, pp.581~586 (2016)
Siyahian A, "Prophylaxis for hepatitis B virus reactivation after allogeneic stem cell transplantation in the era of drug resistance and newer antivirals : a systematic review and meta-analysis", Biol Blood Marrow Transplant, 24, pp.1483~1489 (2018)
Seto WK, "Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation : a prospective study", Hepatology, 65, pp.1451~1461 (2017)
김유진, "Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus", Clinical and Molecular Hepatology, 17(3), pp.199~205 (2011), 대한간학회
최문석, "The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study", Gut and Liver, 6(2), pp.241~248 (2012), 거트앤리버 소화기연관학회협의회[DOI]
Lee LP, "Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients", J Gastroenterol Hepatol, 22, pp.515~517 (2007)
Pol S, "The negative impact of HBV", HCV coinfection on cirrhosis and its consequences, 2017, pp.46, 1054~1060
Chen G, "Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents : a systematic review and meta-analysis", Hepatology, 66, pp.13~26 (2017)
Liu CJ, "Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV", Gastroenterology, 154, pp.989~997 (2018)
Bersoff-Matcha SJ, "Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system", Ann Intern Med, 166, pp.792~798 (2017)
Solas C, "Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients : impact on tenofovir trough concentrations and renal safety", Br J Clin Pharmacol, 84, pp.404~409 (2018)
Thio CL, "HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study(MACS)", Lancet, 360, pp.1921~1926 (2002)
김용찬, "Human Immunodeficiency Virus (HIV) and Hepatitis Virus Coinfection among HIV-Infected Korean Patients: The Korea HIV", AIDS Cohort Study, 2017, pp.49(4), 268~274[DOI]
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection:recommendations for a public health approach, "World Health Organization (WHO)", WHO, 208~ (2016)
Wranke A, "Clinical and virological heterogeneity of hepatitis delta in different regions world-wide : the Hepatitis Delta International Network(HDIN)", Liver Int, 38, pp.842~850 (2018)
정숙향, "우리나라의 D형간염 바이러스 유병률과 임상 양상", Clinical and Molecular Hepatology, 11(2005), pp.43~50 (2005), 대한간학회
Kim HS, "Prevalence and clinical significance of hepatitis D virus coinfection in patients with chronic hepatitis B in Korea", J Med Virol, 83, pp.1172~1177 (2011)
Bahcecioglu IH, "Prevalence of hepatitis delta virus(HDV)infection in chronic hepatitis B patients in eastern Turkey : still a serious problem to consider", J Viral Hepat, 18, pp.518~524 (2011)
Fattovich G, "Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)", Gut, 46, pp.420~426 (2000)
Triantos C, "Metaanalysis : antiviral treatment for hepatitis D", Aliment Pharmacol Ther, 35, pp.663~673 (2012)
Wedemeyer H, "Peginterferon plus adefovir versus either drug alone for hepatitis delta", N Engl J Med, 364, pp.322~331 (2011)
Abbas Z, "Treatment of chronic hepatitis D patients with pegylated interferon : a real-world experience", Antivir Ther, 19, pp.463~468 (2014)
Keskin O, "Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome", Clin Gastroenterol Hepatol, 13, pp.2342~2349 (2015)
Heidrich B, "Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta", Hepatology, 60, pp.87~97 (2014)
Karaca C, "Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response", Antivir Ther, 18, pp.561~566 (2013)
Söderström A, "Hepatitis B virus DNA during pregnancy and post partum : aspects on vertical transmission", Scand J Infect Dis, 35, pp.814~819 (2003)
ter Borg MJ, "Exacerbation of chronic hepatitis B infection after delivery", J Viral Hepat, 15, pp.37~41 (2008)
Samadi Kochaksaraei G, "Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region", J Viral Hepat, 23, pp.15~22 (2016)
Chang CY, "Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B", Am J Gastroenterol, 111, pp.1410~1415 (2016)
Fontana RJ, "Side effects of long-term oral antiviral therapy for hepatitis B", Hepatology, 49(5 Suppl), pp.S185~S195 (2009)
Zhou C, "Motor development delay in offspring is associated with prenatal telbivudine exposure", Medicine (Baltimore), 97, pp.e0053~ (2018)
Jacobson DL, "Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal antiretroviral initiation", Pediatr Infect Dis J, 36, pp.189~197 (2017)
Nguyen G, "Clinical course of hepatitis B virus infection during pregnancy", Aliment Pharmacol Ther, 29, pp.755~764 (2009)
Chang CY, "Serum aminotransferase flares in pregnant and postpartum women with current or prior treatment for chronic hepatitis B", J Clin Gastroenterol, 52, pp.255~261 (2018)
Zhang L, "Breast feeding and immunoprophylaxis efficacy of mother-to-child transmission of hepatitis B virus", J Matern Fetal Neonatal Med, 27, pp.182~186 (2014)
Benaboud S, "Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109TEmAA Study, Step 2", Antimicrob Agents Chemother, 55, pp.1315~1317 (2011)
Mirochnick M, "Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life", J Acquir Immune Defic Syndr, 65, pp.33~41 (2014)
Waitt C, "Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs", J Antimicrob Chemother, 73, pp.1013~1019 (2018)
WHO Technical brief: Preventing HIV during pregnancy and breastfeeding in the context of preexposure prophylaxis (PrEP), "World Health Organization (WHO)", WHO, 10~ (2017)
Wen WH, "Motherto-infant transmission of hepatitis B virus infection : significance of maternal viral load and strategies for intervention", J Hepatol, 59, pp.24~30 (2013)
Zou H, "Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers", J Viral Hepat, 19, pp.e18~e25 (2012)
Yu M, "The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus", Eur J Clin Microbiol Infect Dis, 31, pp.2211~2218 (2012)
Pan CQ, "Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B", Clin Gastroenterol Hepatol, 10, pp.520~526 (2012)
Chen HL, "Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus", Hepatology, 62, pp.375~386 (2015)
Pan CQ, "Tenofovir to prevent hepatitis B transmission in mothers with high viral load", N Engl J Med, 374, pp.2324~2334 (2016)
Hyun MH, "Systematic review with meta-analysis : the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus", Aliment Pharmacol Ther, 45, pp.1493~1505 (2017)
Jourdain G, "Tenofovir versus placebo to prevent perinatal transmission of hepatitis B", N Engl J Med, 378, pp.911~923 (2018)
Kim JH, "The role of tenofovir for prevention of vertical transmission of hepatitis B virus: systematic review with meta-analysis", Gut Liver, 12(Suppl 1), pp.S109~ (2018)
홍석진, "The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection", Pediatric Gastroenterology, Hepatology & Nutrition, 17(1), pp.41~46 (2014), 대한소아소화기영양학회
Wu JF, "Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBVinfected children", J Pediatr Gastroenterol Nutr, 54, pp.97~100 (2012)
Zhu S, "Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics : a pilot open-label randomized study", J Hepatol, 68, pp.1123~1128 (2018)
Jonas MM, "Treatment of children with chronic hepatitis B virus infection in the United States : patient selection and therapeutic options", Hepatology, 52, pp.2192~2205 (2010)
Sokal EM, "Interferon alfa therapy for chronic hepatitis B in children : a multinational randomized controlled trial", Gastroenterology, 114, pp.988~995 (1998)
Kobak GE, "Interferon treatment for chronic hepatitis B : enhanced response in children 5 years old or younger", J Pediatr, 145, pp.340~345 (2004)
Wirth S, "Efficacy and safety of peginterferon alfa-2a(40KD)in children with chronic hepatitis B : the PEG-B-ACTIVE study", Hepatology, 68, pp.1681~1694 (2018)
Jonas MM, "Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B", Hepatology, 63, pp.377~387 (2016)
이경재, "A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B", Journal of Korean Medical Science, 33(8), pp.25~32 (2018), 대한의학회
Murray KF, "Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B", Hepatology, 56, pp.2018~2026 (2012)
최재영, "Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B", Journal of Korean Medical Science, 33(2), pp.24~33 (2018), 대한의학회
Jonas MM, "Clinical trial of lamivudine in children with chronic hepatitis B", N Engl J Med, 346, pp.1706~1713 (2002)
Sokal EM, "Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B", Hepatology, 43, pp.225~232 (2006)
Choe BH, "Longterm therapeutic efficacy of lamivudine compared with interferonalpha in children with chronic hepatitis B : the younger the better", J Pediatr Gastroenterol Nutr, 44, pp.92~98 (2007)
고홍, "Lamivudine Therapy for Korean Children with Chronic Hepatitis B", Yonsei Medical Journal, 48(6), pp.927~933 (2007), 연세대학교의과대학
Chu M, "Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B", J Pediatr Gastroenterol Nutr, 55, pp.648~652 (2012)

이 간행물의 다른 논문 (9건)

Advances in ultrasound diagnosis in chronic liver diseasesNaoya Kato, Hitoshi Maruyamapp. 160-167 Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?Chung-Feng Huang, Ming-Lung Yupp. 168-171 Unmet need in chronic hepatitis B managementLilian Yan Liang, Grace Lai-Hung Wongpp. 172-180 Role of endoscopic treatment or balloon-occluded retrograde transvenous obliteration in patients with Child-Pugh class C end-stage liver cirrhosis and esophageal/gastric varicesJin Wook Chungpp. 181-182 Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosisKazuhide Takata, Shinjiro Inomata, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Takashi Tanaka, Keiji Yokoyama, Ryo Yamauchi, Kumiko Shibata, Hiromi Fukuda, Hideo Kunimotopp. 183-189